The round funds a company that lost RMB2.28 billion from 2022 to 2024 and has yet to list in Hong Kong 17 months after filing in June 2025.
MegaRobo Technologies, a Chinese company that builds robotic laboratories and AI systems for drug discovery and factory quality control, has raised nearly US$200 million in a new round that brings in the Oman Investment Authority (OIA), the sovereign wealth fund of the Sultanate of Oman. Existing backers Asia Investment Capital, Granite Asia and Sinovation Ventures added to their positions, and CMB International joined, the company said in a release dated November 19.
36Kr, which first reported the deal, and Jiemian also list Suzhou Innovation Investment Group (苏创投) and Sanjiang Investment Promotion Group (三江招商集团) as co-investors. 36Kr described the investor mix as international sovereign capital, leading financial institutions and local state-owned industrial capital. No valuation, round name or breakdown by investor was disclosed.
The round lifts MegaRobo’s total funding over its ten years to about US$600 million. It also lands while the company is still waiting to list in Hong Kong: MegaRobo filed for a main board listing in June 2025, and Huang told Bloomberg that the application remains active and "in the queue."
The round adds Gulf money to a cap table led by Chinese venture funds
MegaRobo’s earlier backers are mostly Chinese and Asian venture and growth investors. Its largest previous raise was a Series C of nearly US$300 million co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia, with Pavilion Capital, part of Temasek’s Seviora Group, also taking part, the company said. Sinovation Ventures, Joy Capital and MPCi are described as long-term investors, and pharmaceutical contract research group WuXi AppTec and Bosch Ventures invested earlier as industry backers.
Before the new money, Sinovation held 15.07% of the company, Joy Capital 13.12% and Asia Investment Capital 8.62%, while the founders held 16.08% together, according to a June 2025 Jiemian report on the listing application.
MegaRobo says the new money will go into core technology, overseas expansion of its AI for Science business and infrastructure that lets AI work in more complex physical settings. 36Kr reported that the company plans to deepen work in China, Europe, North America, the Middle East and Southeast Asia.
Revenue doubled in two years while annual losses held near RMB750 million
The figures in MegaRobo’s 2025 prospectus show a company growing quickly but spending heavily. MegaRobo’s revenue rose from RMB455 million in 2022 to RMB930 million in 2024, while its net loss stayed between RMB742 million and RMB780 million a year. The three-year loss totaled RMB2.28 billion, and research and development spending ran between RMB308 million and RMB394 million a year, Jiemian reported. Cash stood at RMB458 million at the end of 2024, and the order backlog was RMB1.5 billion. The joint sponsors were Morgan Stanley, Huatai International, Deutsche Bank and CCB International.
The business has two parts. In science, MegaRobo has delivered automated lab systems to more than 500 customers, including multinational drugmakers, contract research organizations, biotech firms and research institutes, and its Megalaxy Lab (镁伽鲲鹏实验室) has run research for more than 200 customers. One antibody team used the lab to complete 56 design, build and test cycles across 18 drug targets in four months, according to 36Kr. In industry, the company sells AI for defect detection, yield analysis and process tuning to semiconductor, optical interconnect and display makers.
36Kr said MegaRobo sells in two ways: integrated hardware and software platforms that customers install, and a service it calls an AI-native research organization, which runs experiments and delivers research results.
The founder pitches physical experiments as the next way for AI to learn
Founder and chief executive Daniel Huang (黄瑜清) argues that the next generation of AI will learn by acting in the physical world, through experiments, production and feedback, and that MegaRobo is building the infrastructure for that step. He told 36Kr that scientists’ demand for data has outrun the productivity of research labs.
The company is testing that pitch in public. With Tencent Cloud and Twist Bioscience, it launched Poreva Open, a global AI protein design challenge in which Megalaxy Lab will validate more than 10,000 designed protein sequences in its wet labs.
The next marker is whether MegaRobo updates its Hong Kong listing application with financials that reflect the new round. A narrower loss in 2025 results, or a disclosed valuation, would show whether the OIA-backed money is bridging the company to a listing or funding a longer private runway.